Saxenda vs. Wegovy: Why Novo Nordisk Is Discontinuing One of Them

Wait — is Saxenda actually being discontinued?

Yes, and it's worth knowing before anything else on this page. Novo Nordisk has confirmed it's discontinuing Saxenda, with final shipments to wholesalers going out in late January 2027. The company describes it as a strategic portfolio decision, not a safety or quality issue — Saxenda's use has been declining for years as newer, more effective options arrived, and Novo Nordisk is consolidating its weight-management lineup around Wegovy instead.

That doesn't mean Saxenda disappears overnight. Pharmacies will likely have stock for a while after January 2027, and nothing about this changes whether Saxenda is safe to keep using in the meantime. But if you're weighing Saxenda against Wegovy today, or you're already on Saxenda and wondering what comes next, the discontinuation timeline is the single biggest fact shaping that decision — not a footnote to read after the price comparison.

So what's actually different between Saxenda and Wegovy?

Both are Novo Nordisk injections built on the same basic idea — a GLP-1 receptor agonist that slows digestion, curbs appetite signaling in the brain, and helps regulate blood sugar. Where they diverge is the molecule itself. Saxenda is liraglutide, approved for weight management back in 2014. Wegovy is semaglutide, a newer molecule approved in 2021 that Novo Nordisk engineered to stay active in the body far longer.

That difference in how long each molecule persists is the reason for the most obvious practical gap between them: Saxenda is injected once a day, every day, at the same general time. Wegovy is injected once a week. For a lot of women, that alone is the deciding factor — a once-weekly routine is simply easier to sustain for months or years than a daily one, and it's part of why demand has shifted so heavily toward Wegovy since it launched.

Which works better for weight loss — the real trial data

This comparison has genuine head-to-head evidence behind it, which isn't always true of GLP-1 comparisons. The STEP 8 trial, published in JAMA in 2022, put semaglutide (2.4mg weekly) and liraglutide (3.0mg daily — Saxenda's own dose) through the identical 68-week protocol in the same population of adults with overweight or obesity, none of them living with diabetes.

Average weight loss came out to roughly 15.8% of body weight on semaglutide versus roughly 6.4% on liraglutide — more than double. That's not a cross-trial estimate stitched together from two separate studies; it's a direct comparison, which makes it stronger evidence than most of what circulates about GLP-1 drugs. It's also the single biggest reason liraglutide's clinical use has faded industry-wide since Wegovy became available, well before Novo Nordisk's own discontinuation announcement made that shift official.

What does each one actually cost in 2026?

The gap here is almost as wide as the efficacy gap, and for a related reason: Novo Nordisk built a real self-pay infrastructure around Wegovy that Saxenda never got.

Wegovy: a self-pay ladder and a savings card

If you have commercial insurance that covers Wegovy for a documented weight-management diagnosis, the NovoCare Savings Card can bring your monthly cost to around $25, capped at $100 in savings per month. Government insurance — Medicare, Medicaid, TRICARE — doesn't qualify. Without that kind of coverage, NovoCare's own self-pay pharmacy sells Wegovy directly: the pill runs $149 to $299 a month by dose, and the pen starts at $199 a month for the first two fills before settling at $349 (or $399 for the highest-dose HD pen). TrumpRx.gov, the federal direct-purchasing platform that expanded in 2026, lists the identical Novo Nordisk pricing — it's the same program under a different front door, not a separate discount.

Saxenda: no self-pay program, and a fading savings card

Saxenda's list price is $1,349.02 a month, and — unlike Wegovy — it isn't sold through NovoCare's self-pay pharmacy at all; it's simply not one of the medications listed there. Novo Nordisk's own site is also inconsistent about whether a Saxenda savings card still exists: one page describes a card worth up to $200 off a prescription, while a separate, more specific page states plainly that the Saxenda Savings Offer was discontinued for new enrollees back in June 2023, and points patients toward Wegovy's savings program instead. Treat the Saxenda card as effectively gone until you've confirmed otherwise directly with Novo Nordisk. In practice, a GoodRx coupon is the main lever left — reported as low as roughly $372 a month at some pharmacies, though the more typical range runs closer to $1,000 to $1,300.

The budget option neither brand offers: compounded semaglutide

If cost is the deciding factor and you're paying entirely out of pocket, compounded semaglutide — the same molecule behind Wegovy, prepared by a 503A pharmacy instead of shipped as Novo Nordisk's branded pen — undercuts both brands by a wide margin. Fridays runs $150 to $249 a month depending on prepay length, all-in with provider visits and coaching included. It's not FDA-approved Wegovy, and it comes with its own eligibility rules (a documented clinical reason the branded product won't work — cost alone doesn't qualify under current FDA guidance), but it's worth knowing about before assuming Saxenda's list price is the realistic floor.

I'm already on Saxenda — what should I actually do?

Nothing about the January 2027 discontinuation date means you need to stop tomorrow, but it's a reasonable moment to bring up Wegovy with whoever prescribes your Saxenda, especially if refills have already started getting harder to fill at your regular pharmacy. There's no dose-equivalency chart between liraglutide and semaglutide — they're different molecules, not different strengths of the same drug — so most prescribers restart semaglutide at its own lowest introductory dose rather than trying to match wherever you'd titrated to on Saxenda, timing the first weekly dose around your last daily injection so there isn't an overlap. The mechanics of that switch are usually straightforward; the conversation about timing and what to expect is the part worth having directly with your prescriber rather than assuming.

Are the side effects different?

The core side-effect profile is shared, because both drugs work the same way — slowing digestion is the mechanism, not an unwanted extra. Nausea, constipation, diarrhea, and vomiting show up with either drug, usually worst right after a dose increase. In the STEP 8 trial, gastrointestinal side effects were reported at almost identical rates — about 84% on semaglutide versus about 83% on liraglutide — so switching from Saxenda to Wegovy isn't a trade toward a gentler drug on this front, just a different weekly rhythm to the same general pattern.

Where the two may genuinely feel different day to day comes back to dosing frequency. Saxenda's daily injection means any rough patch resets sooner, since the next dose arrives within 24 hours. Wegovy's weekly injection means a difficult stretch after a dose increase can spread out over more of the week before it eases. Neither pattern is universal, and which one a given woman tolerates better isn't something a trial average can predict.

Saxenda vs. Wegovy for perimenopause and menopause weight gain

The metabolic shift a lot of women notice in their 40s and 50s has a clear hormonal driver: falling estrogen worsens insulin resistance and tends to push fat storage toward the abdomen. Both liraglutide and semaglutide act on the same underlying appetite and insulin-sensitivity pathways, so the mechanism isn't different between them here — what changes is which drug you can realistically stay on for the years this transition can take.

No trial has isolated a perimenopausal or postmenopausal subgroup for either drug specifically, so there's no menopause-specific efficacy verdict beyond STEP 8's general result above. But for a woman thinking in years rather than months, a medication the manufacturer has confirmed it's discontinuing isn't something to build a long-term plan around, even if it's worked well so far — which is its own practical reason to have the Wegovy conversation sooner rather than later.

Which one is right for you? Verdict by profile

• You're starting fresh and haven't taken either drug: there's little reason to start with Saxenda now — it's the molecule with the smaller average trial result, the higher list price, and a confirmed end date on the manufacturer's own supply chain.
• You're currently on Saxenda and it's working well: ask your prescriber about a planned switch to Wegovy before January 2027 rather than waiting for a refill to fail — there's no dose-equivalency chart to memorize, and most prescribers restart semaglutide at its own lowest dose regardless of where you left off on liraglutide.
• You want the strongest evidence for weight loss: semaglutide's STEP 8 result is genuine head-to-head evidence, not a cross-trial estimate — more than double Saxenda's average result in the one study that tested them directly.
• A daily routine actually feels more manageable to you than a weekly one: that's a real, individual preference some women have, even knowing the average result is smaller — but it's worth pricing out how long that option will realistically remain available before committing to it.
• Budget is the deciding factor and you're paying out of pocket: compounded semaglutide through a provider like Fridays beats both Saxenda's list price and Wegovy's self-pay ladder on pure cost.